AbbVie set to move office to Sydney CBD in 2026

SYDNEY, AUSTRALIA, Embargoed until 6am AEST 28 January 2026 – AbbVie (NYSE: ABBV) is excited to announce the upcoming relocation of its Sydney office to 321 Kent Street in the heart of the Sydney CBD in Q4 2026. This new, central location reflects AbbVie’s ongoing commitment to building a great workplace for both current and future employees – a workplace where everyone can pursue career growth, engage in meaningful collaboration, and thrive within a vibrant urban setting.

This move signifies more than just a change of address. It is an investment in the future of AbbVie’s unique culture, bringing together its Therapeutics and Aesthetics business operations under one roof for the first time. With the Therapeutics team based in Mascot since 2014 and the Aesthetics team in North Sydney since 2021, co-locating in the CBD will unite AbbVie’s diverse expertise and provide an environment where innovation and cross-functional teamwork can truly flourish.

By relocating to Sydney CBD, AbbVie is not only enhancing access and convenience for its employees but also expanding its reach and reinforcing its position as the top destination for talented professionals in the pharmaceutical industry.

Nathalie McNeil, Vice President and General Manager, AbbVie ANZ, shared: “Moving to the Sydney CBD represents an exciting new chapter for AbbVie in Australia. Collaboration is at the core of our success, and uniting our Therapeutics and Aesthetics teams will enable even greater innovation, ultimately benefiting our people and partners.”

Ellen Qiu, General Manager, Allergan Aesthetics ANZ, added: “This relocation demonstrates AbbVie’s unwavering commitment to building a modern, inspiring workplace. We are energised by the possibilities our new space offers and look forward to shaping the future together as one AbbVie team.”

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services